Mayne Pharma Group (ASX:MYX) spent much of 2025 as a Takeover target, and much of 2026 living with the aftermath of a deal that fell apart. The Adelaide-based specialty pharmaceutical company — focused on women’s health and dermatology, largely in the United States — is now firmly back to charting its own course. For investors, the question of the “next big catalyst” is really about which of several live threads resolves first: the standalone Earnings reset, the fallout from the collapsed bid, or the litigation Mayne is pursuing against its former suitor.

From takeover target to standalone again

In February 2025 Mayne agreed to be acquired by US-based Cosette Pharmaceuticals for AUD 7.40 per share, valuing the company at about AUD 672 million. The deal unravelled over 2025: Cosette sought to walk away citing a material adverse change, the NSW Supreme Court dismissed that claim in October 2025, and the Federal Treasurer then objected to the transaction on national-interest grounds tied to Mayne’s Salisbury Manufacturing site. Mayne issued a termination notice in December 2025.

The shares, which had tracked the AUD 7.40 offer, subsequently traded at a fraction of that level, resetting the market’s view of Mayne as an independent company rather than a bid target.

The FY26 reset

Mayne’s full-year result, reported on 26 August 2026, showed a Business in transition. Group Revenue fell about 6% to AUD 383.7 million, but gross Margin expanded more than four percentage points to 64.7% as the company exited lower-margin generics. Underlying EBITDA declined 27% to AUD 34.2 million, while reported EBITDA of AUD 141.4 million was inflated by one-off items, and the company remained unprofitable at the net line.

The portfolio showed pockets of growth: within women’s health, BIJUVA net sales rose 20% and NEXTSTELLIS grew 6%, though ANNOVERA declined on product returns. Management pointed to improved gross margins and reduced one-off costs in FY27 following the generics exit.

The Cosette overhang — and upside

The legal aftermath is itself a potential catalyst. Mayne received AUD 14.4 million from Cosette in satisfaction of court-ordered legal costs and interest, and in February 2026 filed a broader damages claim against Cosette and related parties over the collapsed deal, with the quantum not publicly disclosed. It has also pointed to entitlement to a break fee. An appeal remains on foot, so the litigation could deliver further recoveries — or drag on for some time yet. For a company of Mayne’s size, even a partial recovery of costs and damages would be financially meaningful, but the timing and outcome are outside its control and should not be treated as a certainty.

Why it matters, and what to watch

Mayne offers exposure to branded women’s health and dermatology products in the large US market, with a cleaner, higher-margin portfolio after the generics exit. Catalysts to watch include the trajectory of underlying EBITDA now that the restructuring is largely done, prescription growth in the key branded products, the ramp of its DistributeRx distribution platform, and any resolution of the Cosette litigation and appeal.

Risks to weigh

The risks are meaningful. Mayne is exposed to US pharmaceutical pricing, competition and product returns, as ANNOVERA showed. Underlying earnings fell in FY26 and the group was loss-making, so the turnaround is unproven. Litigation outcomes are inherently uncertain. And with the takeover premium gone, the shares now rest on operational delivery. Mayne’s next chapter depends less on a single event than on stitching several of these threads into a coherent, profitable standalone story.